KBU2046
Based on 1 Customer Validation
KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma.
For research use only. We do not sell to patients.
- Purity : 98.85%
- CAS No.: 1143863-69-7
- Formula: C15H11FO2
- Molecular Weight:242.25
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
RIPK1 |
ERK1 |
ERK2 |
In Vitro
KBU2046 (1-10 μM; 24-48 h) does not significantly alter the proliferation of MDA-MB-231 or BT-549 TNBC cells[1].
KBU2046 (1-10 μM; 24 h) dose-dependently inhibits TGF-β1-induced motility of MDA-MB-231 and BT-549 TNBC cells, with maximum inhibition at 10 μM, reducing motility to 50.77% and 36.09% of control levels, respectively[1].
KBU2046 (10 μM; 24 h) significantly down-regulates the mRNA expression of LRRC8E, LTBP3, DNAL1, and MAFF in MDA-MB-231 and BT-549 TNBC cells[1].
KBU2046 (1-10 μM; 48 h) dose-dependently suppresses integrin αv and integrin α6 protein expression in MDA-MB-231 and BT-549 TNBC cells, and reverses TGF-β1-mediated up-regulation of these integrins[1].
KBU2046 (10 μM; 15-60 min) time-dependently inhibits phosphorylation of Raf1 and ERK1/2 in MDA-MB-231 and BT-549 TNBC cells, with significant suppression evident within 15 min of treatment[1].
KBU2046 (1-10 μM; 24-48 h) inhibits collective migration of KYSE-30 and KYSE-410 ESCC cells in a time- and concentration-dependent manner[2].
KBU2046 (10 μM; 72 h) inhibits EGF and TGF-β-stimulated single-cell migration and invasion of KYSE-30 and KYSE-410 ESCC cells[2].
KBU2046 (1-10 μM; 72 h) does not inhibit proliferation of KYSE-30 or KYSE-410 ESCC cells after 72-hour incubation[2].
KBU2046 (10 μM; 30 min) inhibits EGF-stimulated phosphorylation of RIPK1 at Ser166 in KYSE-30 and KYSE-410 ESCC cells[2].
KBU2046 (1-10 μM) downregulates ITGA3, ITGA6, and ITGAV expression in KYSE-30 and KYSE-410 ESCC cells in a concentration-dependent manner[2].
KBU2046 (10 μM) selectively modulates expression of motility-related proteins in KYSE-30 ESCC cells, with significant downregulation of integrin family members and other ECM-adhesion proteins that are overexpressed in human ESCC[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231, BT-549 cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:24 h; 48 h;
-
Result:Exhibited no time- or concentration-dependent alterations in cell proliferation in either MDA-MB-231 or BT-549 cells.
-
Cell Line:MDA-MB-231, BT-549 cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:24 h
-
Result:Reduced TGF-β1-induced cellular motility rates to 92.97% at 1 μM, 70.59% at 5 μM, and 50.77% at 10 μM in MDA-MB-231 cells compared to control.
Reduced TGF-β1-induced cellular motility rates to 78.43% at 1 μM, 43.55% at 5 μM, and 36.09% at 10 μM in BT-549 cells compared to control.
-
Cell Line:MDA-MB-231, BT-549 cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:48 h (co-treatment with 10 ng/mL TGF-β1)
-
Result:Reduced integrin αv protein levels to 67.28% at 1 μM, 57.61% at 5 μM, and 42.29% at 10 μM, and integrin α6 levels to 87.15% at 1 μM, 76.54% at 5 μM, and 45.26% at 10 μM in MDA-MB-231 cells compared to control.
Reduced integrin αv levels to 96.13% at 1 μM, 58.68% at 5 μM, and 51.11% at 10 μM, and integrin α6 levels to 82.47% at 1 μM, 66.29% at 5 μM, and 61.89% at 10 μM in BT-549 cells compared to control.
Partially reversed TGF-β1-mediated up-regulation of integrin αv and α6 in both cell lines.
Exhibited no significant effects on integrin α3 or β8 protein levels.
-
Cell Line:MDA-MB-231, BT-549 cells
-
Concentration:10 μM
-
Incubation Time:15 min; 30 min; 60 min
-
Result:Reduced phosphorylation levels of Raf1 (Ser338) and ERK1/2 (Thr202/Tyr204) in a time-dependent manner in both MDA-MB-231 and BT-549 cells.
Showed statistically significant reductions at 15, 30, and 60 min compared to control levels.
-
Cell Line:KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
-
Concentration:1 μM, 10 μM
-
Incubation Time:24 h, 48 h
-
Result:Significantly inhibited wound gap closure in a time- and concentration-dependent manner.
Decreased wound closure by 46.7% in KYSE-30 cells and 47.5% in KYSE-410 cells at 48 h with 10 μM treatment compared to vehicle controls.
-
Cell Line:KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
-
Concentration:1 μM, 10 μM
-
Incubation Time:72 h
-
Result:Had no significant effect on cell viability of KYSE-30 or KYSE-410 cells after 72 h, indicating no inhibition of cell proliferation.
-
Cell Line:EGF-stimulated KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
-
Concentration:10 μM (in the presence of 5 ng/mL EGF)
-
Incubation Time:30 min
-
Result:Markedly inhibited EGF-stimulated phosphorylation of RIPK1 at Ser166 in both KYSE-30 and KYSE-410 cells.
In Vivo
KBU2046 (80 mg/kg; i.g.; every 2 days; 12 total doses) reduces mean ESCC tumor volume to 62% of control levels in male athymic nude mice, without causing significant systemic toxicity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID (male, 4-6 weeks old, 16-18 g, tail vein injection of 1.5×106 KYSE-30 ESCC cells)[2]
-
Dosage:80 mg/kg
-
Administration:p.o.; every other day; 12 total doses
-
Result:Completely inhibited pulmonary metastasis, with 0 of 4 treated mice showing pulmonary metastases compared to 3 of 4 control mice (one-sided t-test, P=0.03).
Showed no significant difference in body weight compared to control group.
Caused no histomorphological changes in heart, liver, or spleen.
-
Animal Model:athymic nude (male, 4-6 weeks old, SPF grade, subcutaneous implantation of 1×106 KYSE-30 ESCC cells into the right flank)[2]
-
Dosage:80 mg/kg
-
Administration:p.o.; every 2 days; 12 total doses
-
Result:Reduced mean tumor volume to 62% of control levels, though the difference was not statistically significant.
Showed no significant difference in body weight compared to control group.
Chemical Information
-
CAS No. 1143863-69-7
-
Appearance Solid
-
Molecular Weight 242.25
-
Formula C15H11FO2
-
Color White to off-white
-
SMILES
O=C1C(C2=CC=C(F)C=C2)COC3=CC=CC=C13
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (206.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen J, et al. Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro. Oncol Res. 2024;32(11):1791-1802. Published 2024 Oct 16. [Content Brief]
[2]. Li K, et al. KBU2046 exerts inhibition on chemokine gradient-mediated motility of esophageal squamous cell carcinoma through reducing integrin expression. Biochim Biophys Acta Mol Basis Dis. 2025;1871(5):167800. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1280 mL | 20.6398 mL | 41.2797 mL | 103.1992 mL |
| 5 mM | 0.8256 mL | 4.1280 mL | 8.2559 mL | 20.6398 mL | |
| 10 mM | 0.4128 mL | 2.0640 mL | 4.1280 mL | 10.3199 mL | |
| 15 mM | 0.2752 mL | 1.3760 mL | 2.7520 mL | 6.8799 mL | |
| 20 mM | 0.2064 mL | 1.0320 mL | 2.0640 mL | 5.1600 mL | |
| 25 mM | 0.1651 mL | 0.8256 mL | 1.6512 mL | 4.1280 mL | |
| 30 mM | 0.1376 mL | 0.6880 mL | 1.3760 mL | 3.4400 mL | |
| 40 mM | 0.1032 mL | 0.5160 mL | 1.0320 mL | 2.5800 mL | |
| 50 mM | 0.0826 mL | 0.4128 mL | 0.8256 mL | 2.0640 mL | |
| 60 mM | 0.0688 mL | 0.3440 mL | 0.6880 mL | 1.7200 mL | |
| 80 mM | 0.0516 mL | 0.2580 mL | 0.5160 mL | 1.2900 mL | |
| 100 mM | 0.0413 mL | 0.2064 mL | 0.4128 mL | 1.0320 mL |